与人类阿波蛋白A-1基因相邻的DNA多态性:与高甘油三血症的关系
Lancet (London, England)
|February 26, 1983
概括
人类阿波蛋白-A-1基因附近的DNA多态性在高甘油三血症患者中更为常见. 这种遗传变异可能表明对高甘油三水平的倾向.
科学领域:
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 脂蛋白A-1 (ApoA-1) 在脂质代谢中起着至关重要的作用.
- 在阿波利波蛋白A-1基因区域的遗传变异可以影响脂质特征.
- 过高甘油三血是心血管疾病的重要危险因素.
研究的目的:
- 研究人类阿波蛋白-A-1基因3'-侧翼区域的特定DNA多态性与高甘油三糖血症之间的关联.
- 确定这种多形态的频率在健康个体和患有高甘油三血症的患者.
主要方法:
- 用DNA测序来识别和基因型的多态.
- 计算了等位基因和基因型频率,并将患者和对照组进行了比较.
主要成果:
- 在人类阿波蛋白-A-1基因的3'-侧翼区域中确定了DNA多态性.
- 在健康对照组中,异合状态的频率约为0.05 (n=73).
- 在高甘油三血症患者 (n=35) 中,多态位点的频率为0.34,其中有2个同卵性个体.
结论:
- 在过高甘油三血症患者中观察到突变异基因的更高频率表明存在潜在的遗传联系.
- 这种多态可能作为阿波蛋白-A-1基因异常的标记,影响ApoA-1表达或结构.
- 这些遗传变化可能会使个体易患过高甘油三血症.
相关概念视频
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


